Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months - 10/03/21
Funding sources: This work was supported by Sun Pharmaceutical Industries, Inc. |
|
Conflicts of interest: Dr Dummer has received research funding from Bristol-Myers Squibb, MSD, Novartis Pharmaceuticals Corporation, Roche, and GlaxoSmithKline; and has served as a consultant or participated on an advisory board for Amgen; Bristol-Myers Squibb; MSD; Novartis Pharmaceuticals Corporation; Roche; GlaxoSmithKline; Sun Pharmaceutical Industries, Inc.; and Takeda. Dr Lear has served as a consultant or speaker for and received honoraria from Novartis Pharmaceuticals Corporation and travel support from Sun Pharmaceutical Industries, Inc. Dr Guminski has participated on advisory boards for Bristol-Myers Squibb, Pfizer, and Sanofi; received honoraria from Novartis Pharmaceuticals Corporation; and received travel support from Astellas and Bristol-Myers Squibb. Author Leow has participated on an advisory board for and received honoraria from Novartis Pharmaceuticals Corporation and has received travel support from Eli Lilly and Company; Janssen Pharmaceuticals; and Sun Pharmaceutical Industries, Inc. Dr Squittieri is an employee of Sun Pharmaceutical Industries, Inc. Dr Migden has participated on advisory boards and received honoraria from Eli Lilly and Company, Genentech Inc, Novartis Pharmaceuticals Corporation, and Regeneron; and has received consulting fees from Sun Pharmaceutical Industries, Inc. |
|
IRB approval status: The study protocol, amendments, and patient-informed consent were approved by individual Institutional Review Boards at each participating study center. |
Vol 84 - N° 4
P. 1162-1164 - avril 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?